Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203172 · ClinicalTrials.gov registry record · Phase 4
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
A Phase 4 study of Solid Tumors, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT05203172: Recruiting Phase 4 study of Solid Tumors, sponsored by Pfizer.
NCT05203172 is a Phase 4 study of Solid Tumors that is actively recruiting participants, run by Pfizer. The registered enrollment target is 46 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05203172, a Phase 4 study of Solid Tumors, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they have not enrolled in a prior study of encorafenib or binimetinib. Participants that had enrolled but had stopped receiving the study treatment in a prior study cannot enrolled in this study. Participants in the FLOTILLA study will receive encorafenib and/or binimetinib at the same dose and frequency as in their prior study, for up to about 5 years.
Conditions Studied
Interventions
- DRUG Binimetinib only treatment
- DRUG Encorafenib only Treatment
- DRUG Encorafenib & Binimetinib Treatment
- DRUG Treatment of Encorafenib & Binimetinib & Ribociclib
- DRUG Treatment of Encorafenib & Binimetinib & Cetuximab
Study Locations (20)
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital - Atlanta
- Investigational Drug Service Emory University Clinic - Atlanta
- Winship Cancer Institute of Emory University - Atlanta
Missouri
- Siteman Cancer Center - St Louis
- Barnes-Jewish Hospital - St Louis
- Washington University School of Medicine - St Louis
- Washington University - St Louis
Minnesota
- HealthPartners Cancer Research Center - Saint Paul
- Regions Hospital Pharmacy - Saint Paul
- HealthPartners Specialty Center - Saint Paul
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- St. Joseph's Hospital and Medical Center - Phoenix
New York
- Rockefeller Outpatient Pavilion (53rd Street) - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke Cancer Center - Durham
- Investigational Chemotherapy Service - Durham
Massachusetts
- Massachusetts General Hospital - Boston
New Jersey
- MSK Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 4 |
What NCT05203172 shows while recruiting
NCT05203172 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Binimetinib only treatment is the first listed.
NCT05203172 names 20 study sites across 9 states, led by Georgia, Missouri, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05203172 about?
NCT05203172 is a clinical study titled "The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials". The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studi...
What is the current status of trial NCT05203172?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2022-07-05. Estimated completion is 2029-07-31.
What conditions does trial NCT05203172 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT05203172?
The interventions under investigation include: Binimetinib only treatment (DRUG), Encorafenib only Treatment (DRUG), Encorafenib & Binimetinib Treatment (DRUG), Treatment of Encorafenib & Binimetinib & Ribociclib (DRUG), Treatment of Encorafenib & Binimetinib & Cetuximab (DRUG).
Who is sponsoring clinical trial NCT05203172?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05203172 being conducted?
This trial has 20 study locations across Arizona, Georgia, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05203172's enrollment target sits among peer trials
46 84th of 125 higher than 41 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RECRUITING · Phase 2
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI